# Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera

> **NCT06193408** · PHASE2 · COMPLETED · sponsor: **Hunazine Biotech S.L.** · enrollment: 150 (actual)

## Conditions studied

- Cholera

## Interventions

- **DRUG:** VR-AD-1005
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06193408
- **Lead sponsor:** Hunazine Biotech S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-11
- **Primary completion:** 2024-08-11
- **Final completion:** 2024-09-08
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06193408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06193408, "Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06193408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*